About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGPhase 4NCT06057402

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab...

Lead sponsor: Pfizer•14 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Pfizer CT.gov Call Center

CONTACT

1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Sponsors

Lead Sponsor

Pfizer

This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants must agree to follow the reproductive criteria as outlined in the protocol
•Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).

Exclusion Criteria

•Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
•Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Related studies

RECRUITINGPhase 2

Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma

NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma

RECRUITINGPhase 3

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)

RECRUITINGPhase 4

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

NCT07030517 · Multiple Myeloma

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more

RECRUITINGPhase 1/2

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945 · Multiple Myeloma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 16, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE4

Enrollment80

Start dateOct 2023

Last updatedApr 16, 2026

Condition

Multiple Myeloma

Locations shown

UCHealth Poudre Valley Hospital

Fort Collins, Colorado

UCHealth Harmony

Fort Collins, Colorado

UCHealth Greeley Hospital

Greeley, Colorado

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions